{"preliminary_commentary":{"by_channel":{"x_thread":3,"youtube":2,"podcast":2},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"name":"NRG-GY017","nct_id":"NCT03738228","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nrg-gy017-nct03738228. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Patients receive atezolizumab IV over 30-60 minutes on days -21, 0, and 21 in the absence of disease progression or unacceptable toxicity. Patients also receive standard of care cisplatin chemotherapy IV over 90 minutes on days 0, 7, 14, 21, 28, and 35. Beginning on day 0, patients also receive standard of care radiation therapy once daily (Monday-Friday) for a total of 25 fractions with image guided brachytherapy beginning in week 4, 5, or at the end of radiation therapy.","label":"Arm A (atezolizumab, standard cisplatin and radiation therapy)","type":"EXPERIMENTAL"},{"description":"Patients receive atezolizumab IV over 30-60 minutes on days 0, 21, and 42 in the absence of disease progression or unacceptable toxicity. Patients also receive standard of care cisplatin chemotherapy, radiation therapy, and image guided brachytherapy as in Arm A.","label":"Arm B (atezolizumab, standard cisplatin and radiation therapy)","type":"EXPERIMENTAL"}],"collaborators":["NRG Oncology"],"completion_date":{"date":"2025-09-12","type":"ACTUAL"},"conditions":["Cervical Adenocarcinoma","Cervical Adenosquamous Carcinoma","Cervical Squamous Cell Carcinoma","Stage IB2 Cervical Cancer AJCC v8","Stage II Cervical Cancer AJCC v8","Stage IIA Cervical Cancer AJCC v8","Stage IIA1 Cervical Cancer AJCC v8","Stage IIA2 Cervical Cancer AJCC v8","Stage IIB Cervical Cancer AJCC v8","Stage IIIB Cervical Cancer AJCC v8","Stage IVA Cervical Cancer AJCC v8"],"enrollment":{"count":40,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Atezolizumab","otherNames":["MPDL 3280A","MPDL 328OA","MPDL-3280A","MPDL3280A","MPDL328OA","RG 7446","RG-7446","RG7446","RO 5541267","RO-5541267","RO5541267","Tecentriq"],"type":"DRUG"},{"name":"Brachytherapy","otherNames":["Brachytherapy, NOS","Internal Radiation","Internal Radiation Brachytherapy","Internal Radiation Therapy","Radiation Brachytherapy","Radiation, Internal"],"type":"RADIATION"},{"name":"Cisplatin","otherNames":["Abiplatin","Blastolem","Briplatin","CDDP","Cis-diammine-dichloroplatinum","Cis-diamminedichloridoplatinum","Cis-diamminedichloro Platinum (II)","Cis-diamminedichloroplatinum","Cis-dichloroammine Platinum (II)","Cis-platinous Diamine Dichloride","Cis-platinum","Cis-platinum II","Cis-platinum II Diamine Dichloride","Cismaplat","Cisplatina","Cisplatinum","Cisplatyl","Citoplatino","Citosin","Cysplatyna","DDP","Lederplatin","Metaplatin","Neoplatin","Peyrone's Chloride","Peyrone's Salt","Placis","Plastistil","Platamine","Platiblastin","Platiblastin-S","Platinex","Platinol","Platinol- AQ","Platinol-AQ","Platinol-AQ VHA Plus","Platinoxan","Platinum","Platinum Diamminodichloride","Platiran","Platistin","Platosin"],"type":"DRUG"},{"name":"Radiation Therapy","otherNames":["Cancer Radiotherapy","Energy Type","ENERGY_TYPE","Irradiate","Irradiated","Irradiation","Radiation","Radiation Therapy, NOS","Radiotherapeutics","Radiotherapy","RT","Therapy, Radiation"],"type":"RADIATION"}],"last_update":"2025-11-12","lead_sponsor":"National Cancer Institute (NCI)","official_title":"Anti PD-L1 (Atezolizumab) as an Immune Primer and Concurrently With Extended Field Chemoradiotherapy for Node Positive Locally Advanced Cervical Cancer","overall_status":"COMPLETED","phases":["PHASE1"],"primary_completion_date":{"date":"2022-05-01","type":"ACTUAL"},"primary_outcomes":[{"measure":"Immune Response","timeFrame":"Arm A: 42 days from the first dose of Atezolizumab Arm B: 21 days from the first dose of Atezolizumab"}],"references":[{"citation":"Mayadev J, Zamarin D, Deng W, Lankes H, O'Cearbhaill R, Aghajanian CA, Schilder R. Anti-PD-L1 (atezolizumab) as an immune primer and concurrently with extended-field chemoradiotherapy for node-positive locally advanced cervical cancer. Int J Gynecol Cancer. 2020 May;30(5):701-704. doi: 10.1136/ijgc-2019-001012. Epub 2019 Dec 22.","pmid":"31871115","type":"DERIVED"}],"start_date":{"date":"2019-01-07","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Atezolizumab Before and/or With Chemoradiotherapy in Immune System Activation in Patients With Node Positive Stage IB2, II, IIIB, or IVA Cervical Cancer","url":"https://clinicaltrials.gov/study/NCT03738228"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nrg-gy017-nct03738228"}